GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)

INR 2303.2

(-1.26%)

Operating Expenses Summary of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited's latest annual operating expenses in 2023 was 4.35 Billion INR , down -64.53% from previous year.
GlaxoSmithKline Pharmaceuticals Limited's latest quarterly operating expenses in 2024 Q2 was 3.21 Billion INR , up 11.85% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a annual operating expenses of 12.28 Billion INR in annual operating expenses 2022, up 8.75% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a annual operating expenses of 11.29 Billion INR in annual operating expenses 2021, down -2.06% from previous year.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating expenses of 3.21 Billion INR for 2024 Q2, up 11.85% from previous quarter.
GlaxoSmithKline Pharmaceuticals Limited reported a quarterly operating expenses of 2.87 Billion INR for 2023 Q3, down -13.2% from previous quarter.

Annual Operating Expenses Chart of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Historical Annual Operating Expenses of GlaxoSmithKline Pharmaceuticals Limited (2023 - 2004)

Year	Operating Expenses	Operating Expenses Growth
2023	4.35 Billion INR	-64.53%
2022	12.28 Billion INR	8.75%
2021	11.29 Billion INR	-2.06%
2020	11.53 Billion INR	-14.41%
2019	13.47 Billion INR	19.57%
2018	11.27 Billion INR	5.61%
2017	10.67 Billion INR	3.19%
2016	10.34 Billion INR	7.05%
2015	9.65 Billion INR	-0.07%
2014	9.66 Billion INR	19.97%
2013	8.05 Billion INR	15.46%
2012	6.97 Billion INR	31.23%
2011	5.31 Billion INR	8.25%
2010	4.91 Billion INR	10.55%
2009	4.44 Billion INR	32.03%
2008	3.36 Billion INR	-2.16%
2007	3.44 Billion INR	-10.45%
2006	3.84 Billion INR	-1.79%
2005	3.91 Billion INR	3.41%
2004	3.78 Billion INR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q1	1.37 Billion INR	3.76%
2024 Q2	3.21 Billion INR	11.85%
2023 Q3	2.87 Billion INR	-13.2%
2023 FY	4.35 Billion INR	-64.53%
2023 Q4	1.32 Billion INR	-53.88%
2023 Q1	3.38 Billion INR	16.52%
2023 Q2	3.31 Billion INR	-2.03%
2022 FY	12.28 Billion INR	8.75%
2022 Q2	3.11 Billion INR	-4.28%
2022 Q1	3.25 Billion INR	62.72%
2022 Q3	3.01 Billion INR	-2.98%
2022 Q4	2.9 Billion INR	-3.92%
2021 Q4	1.99 Billion INR	-36.74%
2021 Q1	3.45 Billion INR	66.92%
2021 FY	11.29 Billion INR	-2.06%
2021 Q2	3.47 Billion INR	0.56%
2021 Q3	3.15 Billion INR	-9.21%
2020 Q1	2.98 Billion INR	-14.81%
2020 FY	11.53 Billion INR	-14.41%
2020 Q4	2.07 Billion INR	-32.98%
2020 Q3	3.09 Billion INR	-6.0%
2020 Q2	3.28 Billion INR	10.03%
2019 Q3	3.44 Billion INR	1.16%
2019 FY	13.47 Billion INR	19.57%
2019 Q4	3.5 Billion INR	1.79%
2019 Q1	3.1 Billion INR	51.28%
2019 Q2	3.4 Billion INR	9.61%
2018 Q2	3.13 Billion INR	8.2%
2018 FY	11.27 Billion INR	5.61%
2018 Q4	2.05 Billion INR	-35.3%
2018 Q3	3.17 Billion INR	1.27%
2018 Q1	2.89 Billion INR	0.0%
2017 FY	10.67 Billion INR	3.19%
2017 Q1	2.99 Billion INR	0.0%
2016 FY	10.34 Billion INR	7.05%
2015 FY	9.65 Billion INR	-0.07%
2014 FY	9.66 Billion INR	19.97%
2013 FY	8.05 Billion INR	15.46%
2012 FY	6.97 Billion INR	31.23%
2011 FY	5.31 Billion INR	8.25%
2010 FY	4.91 Billion INR	10.55%
2009 FY	4.44 Billion INR	32.03%
2008 FY	3.36 Billion INR	-2.16%
2007 FY	3.44 Billion INR	-10.45%
2006 FY	3.84 Billion INR	-1.79%
2005 FY	3.91 Billion INR	3.41%
2004 FY	3.78 Billion INR	0.0%

Peer Operating Expenses Comparison of GlaxoSmithKline Pharmaceuticals Limited

Name	Operating Expenses	Operating Expenses Difference
Abbott India Limited	5.98 Billion INR	27.21%
Cipla Limited	59.21 Billion INR	92.642%
Gland Pharma Limited	14.65 Billion INR	70.27%
Kopran Limited	1.41 Billion INR	-207.767%
Marksans Pharma Limited	3.28 Billion INR	-32.465%
NGL Fine-Chem Limited	1.75 Billion INR	-148.956%
Pfizer Limited	4.33 Billion INR	-0.465%
Sanofi India Limited	4.13 Billion INR	-5.454%
SMS Pharmaceuticals Limited	769.2 Million INR	-466.475%
TTK Healthcare Limited	3.72 Billion INR	-17.091%